ebook Munafa Stock Market Course + Intraday & FNO calls  

       

524816 announcements Natco Pharm announcements and dividends declared BSE

Natco Pharm Complete list of announcements declared & dividend announcements by Natco Pharm 524816

Natco Pharm 524816 listed on BSE and deals in

Announcements and dividends declared by Natco Pharm 524816

Natco Pharma launches generic drug with 180-day exclusivity in US
Natco Pharma has launched Bosentan tablets, a generic version of Tracleer, in the US for treating pulmonary arterial hypertension in young patients. This launch comes with 180-day exclusivity. Lupin Ltd. is Natco's marketing partner for this product. The d
Announcement as on 20 August 2025

Natco Pharma to buy over 35% in South Africa's Adcock Ingram
Natco Pharma, based in Hyderabad, is set to acquire a 35.75% stake in Adcock Ingram, South Africa's second-largest drugmaker, for ₹2,000 crore. This all-cash deal provides Natco Pharma with a strong entry into high-growth African markets and expands its
Announcement as on 24 July 2025

Natco Pharma offers to acquire nearly 36% stake in Adcock Ingram in Rs 2,100-cr deal
Natco Pharma has made a firm offer to acquire nearly 36% stake in South African drug firm Adcock Ingram Holdings for up to Rs 2,100 crore. This acquisition will provide Natco Pharma with a strong entry into the Southern African market and expand its footpr
Announcement as on 23 July 2025

Delhi HC asks Natco Pharma to pause Risdiplam launch amid patent dispute
The Delhi High Court has ordered Natco Pharma to maintain status quo on the launch of Risdiplam until April 2. Roche, which holds the patent for the drug, sought an injunction to prevent Natco from manufacturing it in India. The court highlighted the publi
Announcement as on 26 March 2025

Delhi HC rejects Roche's plea to block Natco Pharma on Risdiplam patent
The Delhi High Court denied Roche's request to temporarily restrain Natco Pharma from producing its spinal muscular atrophy drug, citing public interest and high prices. Natco is required to maintain detailed financial records and may owe damages if Roche
Announcement as on 24 March 2025

Announcements by Natco Pharm first page | Next page | Prev page |

524816 Natco Pharm current price & indicator signals

Moving Averages for Natco Pharm

  • 5Day Average: 927.59
  • 12Day Average: 936.37
  • 20Day Average: 949.37
  • 50Day Average: 951.54
  • 100Day Average: 1007.24
  • 150Day Average: 964.51
  • 200Day Average: 936.95

524816 Indicators & signals

Indicator MACD (12,26,9)

934.15, 941.03, -4.92
Indicator MACD is in negative zone

Indicator ADX (14)

4.73, 17.95, 19.74
Indicator ADX is indicating that momentum is weak.
Momentum is towards selling.

Indicator RSI (14)

Current RSI is: 49
Indicator RSI is indicating buying momentum and stock might rise.

Recent prices of 524816 Natco Pharm are as follows: Daily volume is divided by 10 day averaged volume

Date Close Range Change % Volume
31 Fri Jul 2026 919.85 914.00 to 936.15 -1.17% 0.46 times
30 Thu Jul 2026 930.70 926.10 to 945.00 -0.52% 0.34 times
29 Wed Jul 2026 935.60 925.70 to 941.10 1.18% 0.27 times
28 Tue Jul 2026 924.65 920.40 to 934.85 -0.27% 0.74 times
27 Mon Jul 2026 927.15 921.45 to 938.35 0.69% 0.31 times
24 Fri Jul 2026 920.80 911.70 to 926.90 0.21% 0.96 times
23 Thu Jul 2026 918.85 916.45 to 938.00 -1.71% 1.18 times
22 Wed Jul 2026 934.80 927.40 to 955.10 -2.82% 1.61 times
21 Tue Jul 2026 961.95 949.40 to 965.05 1.2% 0.43 times
20 Mon Jul 2026 950.55 948.50 to 986.00 0.51% 2.07 times
17 Fri Jul 2026 945.75 941.65 to 974.75 -2.07% 2.1 times
16 Thu Jul 2026 965.75 960.00 to 982.50 -0.41% 0.58 times

Videos related to: 524816 announcements Natco Pharm announcements and dividends declared BSE

Hindi Video Correct Way Of Fundamental Analysis Using EPS And PE - MunafaSutra

Hindi Video What Is Needed To Succeed In Stock Markets

524816 announcements Natco Pharm announcements and dividends declared BSE

 

Back to top